ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers

Contributed by: Business Wire

Logo

Tags

Research

Genetics

Clinical Trials

Stem Cells

Biotechnology

Health

Pharmaceutical

Science

Oncology

More Like This

ViroCell Biologics Completes Oversubscribed Financing

ViroCell Manufactured a GMP Lentiviral Vector for UCL to Accelerate Research Into Prevention of Relapse in Childhood Blood Cancer

ViroCell Biologics Signs Master Services Agreement With Prominent NCI-Designated Cancer Center

PR Newswire associated0

AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T Program

PR Newswire associated0

AvenCell Announces First Patient Dosed in a Phase IA Study with lead product candidate AVC-201, a Novel Allogeneic CD123-Directed Switchable CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia and other CD123 Hematological Malignancies

ViroCell Biologics Expands U.S. Business Development Team With Two New Appointments

ViroCell Biologics Appoints Viral Vector Expert as Special Advisor

ViroCell and Great Ormond Street Hospital Poised to Unlock Clinical Trial ‘Backlog’ Following MHRA Manufacturing Approval